Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial-Reference-Cited by-同舟云学术

Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial

Published:2018-04 Issue:4 Volume:5 Page:e136-e146
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Ohanian Maro,Tari Ashizawa Ana,Garcia-Manero Guillermo,Pemmaraju Naveen,Kadia Tapan,Jabbour Elias,Ravandi Farhad,Borthakur Gautam,Andreeff Michael,Konopleva Marina,Lim Miranda,Pierce Sherry,O'Brien Susan,Alvarado Yesid,Verstovsek Srdan,Wierda William,Kantarjian Hagop,Cortes Jorge

Publisher

Elsevier BV

Subject

Hematology

Reference34 articles.

1. Chromosome abnormalities in malignant hematologic disorders;Dewald;Mayo Clin Proc,1985

2. Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53;Kanagal-Shamanna;Cancer,2012

3. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling;Lowenstein;Cell,1992

4. A Drosophila SH2-SH3 adaptor protein implicated in coupling the sevenless tyrosine kinase to an activator of Ras guanine nucleotide exchange, Sos;Olivier;Cell,1993

5. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway;Puil;EMBO J,1994

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancing cancer treatments: The role of oligonucleotide-based therapies in driving progress;Molecular Therapy - Nucleic Acids;2024-09

2. BP1003 Decreases STAT3 Expression and Its Pro-Tumorigenic Functions in Solid Tumors and the Tumor Microenvironment;Biomedicines;2024-08-20

3. RNA-encapsulating lipid nanoparticles in cancer immunotherapy: From pre-clinical studies to clinical trials;European Journal of Pharmaceutics and Biopharmaceutics;2024-04

4. Distinguishing Acute Leukemia Subtypes: The Role of hsa_circ_0012152 and hsa_circ_0020093 in Peripheral Blood;2024-03-06

5. Nucleic acid therapeutics as differentiation agents for myeloid leukemias;Leukemia;2024-02-29